Viatris has confirmed that the recent US approval for its Breyna generic version of AstraZeneca’s Symbicort (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler “presents an opportunity” for market entry in 2022, albeit “as upcoming court proceedings develop.”
The US Court of Appeals for the Federal Circuit had earlier vacated and remanded Viatris’ earlier stipulated judgment of infringement entered at the district court level of three Symbicort patents, presenting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?